Michael Rieder

Michael Rieder

Auto-generated profile, based on publicly available information

Michael Rieder

University of Western Ontario

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2015 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
KBKlr Brouwer
Klr Brouwer
LALauren Aleksunes
Lauren Aleksunes
BBB Brandys
B Brandys
GGGp Giacoia
Gp Giacoia
GKG Knipp
G Knipp
OGon behalf of the Pediatric Transporter Working Group
on behalf of the Pediatric Transporter Working Group

7 February 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
CBCharlotte I. S. Barker
Charlotte I. S. Barker
GGGabriella Groeneweg
Gabriella Groeneweg
AZAnke H. Maitland‐Van der Zee
Anke H. Maitland‐Van der Zee
MRMichael J. Rieder
Michael J. Rieder
DHDan Hawcutt
Dan Hawcutt
BCBruce Carleton
Bruce Carleton
Pharmacogenomics (PGx) relates to the study of genetic factors determining variability in drug response. Implementing PGx testing in paediatric patients can enhance drug safety, helping to improve drug efficacy or reduce the risk of toxicity. Despite its clinical relevance, the implementation of PGx testing in paediatric practice to date has been variable and limited.As with most paediatric pharmacological studies, there are well‐recognised barriers to obtaining high‐quality PGx evidence, particularly when patient numbers may be small, and off‐label or unlicensed prescribing remains widespread. Furthermore, trials enrolling small numbers of children can rarely, in isolation, provide sufficient PGx evidence to change clinical practice, so extrapolation from larger PGx studies in adult patients, where scientifically sound, is essential.This review paper discusses the relevance of PGx to paediatrics and considers implementation strategies from a child health perspective. Examples are provided from Canada, the Netherlands and the UK, with consideration of the different healthcare systems and their distinct approaches to implementation, followed by future recommendations based on these cumulative experiences.Improving the evidence base demonstrating the clinical utility and cost‐effectiveness of paediatric PGx testing will be critical to drive implementation forwards. International, interdisciplinary collaborations will enhance paediatric data collation, interpretation and evidence curation, while also supporting dedicated paediatric PGx educational initiatives. PGx consortia and paediatric clinical research networks will continue to play a central role in the streamlined development of effective PGx implementation strategies to help optimise paediatric pharmacotherapy.

1 January 2010 in Drug News & Perspectives
Verified
Journal Article
Closed access
MRM. Rieder
M. Rieder
Specific drug therapy has created paradigm changes in the cure and control of many common and important diseases. However, the benefits of specific therapy have not been shared equally, and children have been especially disadvantaged. In addition to many drugs lacking pediatric-specific information on drug safety and efficacy, there is often a lack of child-friendly formulations. Practical challenges include issues of stability and palatability, while other issues include variations in drug metabolism and excretion in different populations of children and policy issues related to the fact that the largest number of children live in the developing world. Innovations in drug formulations offer the potential for addressing the practical issues, while changes in public policy offer the potential for all the world's children to share more equally in the benefits of pharmacotherapy.

18 April 2007 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
DLD Lin
D Lin
WLW K Li
W K Li
MRM J Rieder
M J Rieder

1 January 2019 in The Journal of Pediatric Pharmacology and Therapeutics
Verified
Journal Article
Closed access
MRMichael Rieder
Michael Rieder
An underappreciated problem in child health is the risk for adverse drug reactions (ADRs). While there is an impression that children are at a lower risk than adults for ADRs, in fact a number of factors germane to pediatric therapy place certain groups of children at a high risk for adverse events associated with therapy. Given the importance of drug safety, an understanding of a diagnostic classification for ADRs and of how to approach a possible ADR clinically are key skills for pediatric pharmacists. As drug therapy for children evolves, becomes more complex, and begins to use novel molecules and biologicals there will be an increasing need for pediatric pharmacists to be more involved in clinical care, education, and research specific to drug safety.

1 June 2015 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
AEAbdelbaset A. Elzagallaai
Abdelbaset A. Elzagallaai
MRMichael J. Rieder
Michael J. Rieder